• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Assembly Biosciences, Inc. - Common Stock (NQ:ASMB)

    30.57 -0.82 (-2.63%)
    Streaming Delayed Price Updated: 11:06 AM EST, Jan 8, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 23,273
    Open 31.07
    Bid (Size) 30.30 (400)
    Ask (Size) 30.83 (900)
    Prev. Close 31.39
    Today's Range 30.34 - 31.50
    52wk Range 7.750 - 39.70
    Shares Outstanding 52,121,309
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Assembly Biosciences Stock Jumps After Wall Street Says Gilead Opt-In ‘Significantly De-Risks’ Genital Herpes Programs ↗
    Via Stocktwits
    News headline image
    Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
    From Gilead Sciences, Inc.
    Via Business Wire

    Performance

    YTD
    -9.4%
    -9.4%
    1 Month
    -13.6%
    -13.6%
    3 Month
    +19.9%
    +19.9%
    6 Month
    +63.3%
    +63.3%
    1 Year
    +76.0%
    +76.0%

    More News

    Read More
    News headline image
    Assembly Biosciences Inc (NASDAQ:ASMB) Fits the Minervini Trend Template with Strong Growth Fundamentals ↗
    Via Chartmill
    News headline image
    Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Inc (NASDAQ:ASMB) Fits the Minervini Trend Template with High Growth Momentum ↗
    Via Chartmill
    News headline image
    Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Forecasting The Future: 4 Analyst Projections For Assembly Biosciences ↗
    Via Benzinga
    News headline image
    Assembly Biosciences Announces Upcoming Investor Conference Participation
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
    Via Benzinga
    News headline image
    Assembly Biosciences Announces Pricing of $175 Million in Equity Financings
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    New Preclinical Data for Assembly Biosciences’ Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress
    From Assembly Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    This Clearway Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
    Via Benzinga

    Frequently Asked Questions

    Is Assembly Biosciences, Inc. - Common Stock publicly traded?
    Yes, Assembly Biosciences, Inc. - Common Stock is publicly traded.
    What exchange does Assembly Biosciences, Inc. - Common Stock trade on?
    Assembly Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Assembly Biosciences, Inc. - Common Stock?
    The ticker symbol for Assembly Biosciences, Inc. - Common Stock is ASMB on the Nasdaq Stock Market
    What is the current price of Assembly Biosciences, Inc. - Common Stock?
    The current price of Assembly Biosciences, Inc. - Common Stock is 30.57
    When was Assembly Biosciences, Inc. - Common Stock last traded?
    The last trade of Assembly Biosciences, Inc. - Common Stock was at 01/08/26 11:06 AM ET
    What is the market capitalization of Assembly Biosciences, Inc. - Common Stock?
    The market capitalization of Assembly Biosciences, Inc. - Common Stock is 1.59B
    How many shares of Assembly Biosciences, Inc. - Common Stock are outstanding?
    Assembly Biosciences, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.